ArticleKidney international2025
Evaluation of methodologies in anti-nephrin autoantibody detection.
Article in Kidney international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Association between anti-nephrin autoantibodies and disease activity in minimal change disease.Annals of medicine · 2026Article
- Anti-nephrin autoantibodies in post-transplant recurrence of focal segmental glomerulosclerosis: a review.Renal failure · 2026Review
- Anti-CD20 Therapies and Antinephrin Autoantibodies in IgA Nephropathy With Minimal Change Disease.Kidney international reports · 2026Article
- Dual anti-CD20/anti-CD38 therapy for severe recurrent FSGS with longitudinal anti-nephrin assessment.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2026Article
- Anti-nephrin antibodies are not enriched in patients with primary and posttransplant recurrent podocytopathies.The Journal of clinical investigation · 2026Observational
- Nephrin autoimmunity: signal, noise, and a path to clarity.The Journal of clinical investigation · 2026Article
- Anti-nephrin antibodies in pediatric nephrotic syndrome: a new paradigm.Pediatric nephrology (Berlin, Germany) · 2026Review
- Combined Anti-CD20/Anti-CD38 Therapy in Posttransplant Focal Segmental Glomerulosclerosis Recurrence: A Retrospective, International, Multicenter Study.Transplantation direct · 2026Article
- Afucosylated IgG in idiopathic nephrotic syndrome patients with anti-nephrin autoantibodies correlate with disease activity.Journal of translational autoimmunity · 2025Article
- Serum Factors in Primary Podocytopathies.Antibodies (Basel, Switzerland) · 2025Review
- The Use of Rituximab in Glomerulonephritis: What Is the Evidence?Biomedicines · 2025Review
- Potential and pitfalls of measuring circulating anti-nephrin autoantibodies in glomerular diseases.Clinical kidney journal · 2025Review
- Quo Vadis Standardization of Anti-Nephrin Antibody Detection?Glomerular diseasesArticle
Corrections and comments
- Update of
Authors and funding
12 authors.
Funding
Abstract
introductionRecent studies discovered the prominent presence of anti-nephrin autoantibodies in minimal change disease (MCD) and focal segmental glomerulosclerosis (FSGS). However, widely different and often unconventional autoantibody detection methods were used in these studies, making it challenging to standardize anti-nephrin antibody detection and quantification across different studies.
methodsHere, we compare methods of conventional ELISA, immunoprecipitation (IP)-based on-beads ELISA, immunoprecipitation-Western blotting (IP-WB), and cell- and tissue-based immunofluorescence staining with two cohorts totaling 169 patients and control individuals.
resultsDifferent assay methods and antigen preparations led to method-specific false-positive and false-negative results. In general, high-quality antigens produced in human cells, combined with IP-based assays, yielded the most robust and reliable results. Among 63 and 24 samples from patients with FSGS or MCD, respectively, two patients with FSGS showed strong antibody signals in both ELISA-based assays and IP-WB, while approximately half of patients with MCD had weak signals detectable only by IP-WB.
conclusionsThese findings highlight the importance of standardizing antibody detection methods.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.